MONARCH 3: Final overall survival results of abemaciclib plus a nonsteroidal aromatase inhibitor as first-line therapy for HR+, HER2-advanced breast cancer

被引：2
|
作者：
Goetz, Matthew
Toi, Masakazu
Huober, Jens
Sohn, Joo Hyuk
Tredan, Olivier
Park, Inhae
Campone, Mario
Chen, Shin-Cheh
Manso, Luis Manual
Paluch-Shimon, Shani
Freedman, Orit C.
Andre, Valerie
Saha, Abhijoy
van Hal, Gertjan
Shahir, Ashwin
Iwata, Hiroji
Johnston, Stephen R. D.
O'Shaughnessy, Joyce
Pivot, Xavier
Tolaney, Sara
Hurvitz, Sara
Llombart, Antonio
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-GS01-12
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
GS01-12
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Everolimus plus exemestane as first-line therapy in HR+, HER2− advanced breast cancer in BOLERO-2
    J. Thaddeus Beck
    Gabriel N. Hortobagyi
    Mario Campone
    Fabienne Lebrun
    Ines Deleu
    Hope S. Rugo
    Barbara Pistilli
    Norikazu Masuda
    Lowell Hart
    Bohuslav Melichar
    Shaker Dakhil
    Matthias Geberth
    Martina Nunzi
    Daniel Y. C. Heng
    Thomas Brechenmacher
    Mona El-Hashimy
    Shyanne Douma
    Francois Ringeisen
    Martine Piccart
    Breast Cancer Research and Treatment, 2014, 143 : 459 - 467
  • [42] Everolimus plus exemestane as first-line therapy in HR+, HER2- advanced breast cancer in BOLERO-2
    Beck, J. Thaddeus
    Hortobagyi, Gabriel N.
    Campone, Mario
    Lebrun, Fabienne
    Deleu, Ines
    Rugo, Hope S.
    Pistilli, Barbara
    Masuda, Norikazu
    Hart, Lowell
    Melichar, Bohuslav
    Dakhil, Shaker
    Geberth, Matthias
    Nunzi, Martina
    Heng, Daniel Y. C.
    Brechenmacher, Thomas
    El-Hashimy, Mona
    Douma, Shyanne
    Ringeisen, Francois
    Piccart, Martine
    BREAST CANCER RESEARCH AND TREATMENT, 2014, 143 (03) : 459 - 467
  • [43] Health-related quality of life (HRQoL) in MONARCH 2: Abemaciclib plus fulvestrant in women with HR+, HER2-advanced breast cancer (ABC) who progressed on endocrine therapy
    Kaufman, Peter A.
    Toi, Masakazu
    Neven, Patrick
    Sohn, Joohyuk
    Price, Gregory L.
    Lin, Yong
    Boye, Mark
    Li, Li
    Gable, Jonathon
    Carter, Gebra Cuyun
    Sledge, George W.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [44] Palbociclib plus endocrine therapy in HR+/HER2-advanced breast cancer patients: Interim results of the PERFORM study
    Radosa, J. C.
    Fietz, T.
    Wilke, J.
    Decker, T.
    Petersen, V.
    Deryal, M.
    Knoblich, J.
    Losem, C.
    Rhein, U.
    Schoettker, B.
    Wrobel, D.
    Pfeiler, G.
    Zanucco, E.
    Buncke, J.
    Woerner, S.
    Gratzke, K.
    Adams, A.
    Glastetter, E.
    Bartsch, R.
    Lux, M. P.
    ANNALS OF ONCOLOGY, 2023, 34 : S353 - S354
  • [45] Dalpiciclib plus letrozole or anastrozole as first-line treatment for HR+/HER2-advanced breast cancer (DAWNA-2): A phase III trial
    Xu, B.
    Zhang, Q. Y.
    Zhang, P.
    Tong, Z.
    Sun, T.
    Li, W.
    Ouyang, Q.
    Hu, X.
    Cheng, Y.
    Yan, M.
    Teng, Y.
    Pan, Y.
    Yan, X.
    Wang, Y.
    Xie, W.
    Zeng, X.
    Jiang, S.
    Bayaxi, N.
    Zhu, X.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1384 - S1385
  • [46] Time trends in overall survival and systemic therapy in patients with HR+/HER2-advanced breast cancer: A study of the SONABRE registry
    Meegdes, M.
    Geurts, S. M. E.
    Erdkamp, F. L. G.
    Dercksen, W.
    Vriens, B. E. P. J.
    Aaldering, K. N. A.
    Pepels, M. J. A. E.
    Winkel, L. V. D.
    Tol, J.
    Heijns, J. B.
    van de Wouw, A. J.
    Peters, N.
    Fallois, A. J. O.
    van Kats, M. A. C. E.
    Tjan-Heijnen, V. C. G.
    ANNALS OF ONCOLOGY, 2022, 33 : S209 - S209
  • [47] Ribociclib Shows Sustained Overall Survival Benefit in Postmenopausal Women with HR+/HER2-Advanced Breast Cancer
    不详
    ONCOLOGIST, 2021, 26 : S7 - S8
  • [48] Overall survival in Japanese patients with ER+/HER2-advanced breast cancer treated with first-line palbociclib plus letrozole
    Takahashi, Masato
    Osako, Tomofumi
    Yasojima, Hiroyuki
    Inoue, Kenichi
    Kawashima, Masahiro
    Maeda, Hideki
    Ichikawa, Akemi
    Muramatsu, Yasuaki
    Masuda, Norikazu
    BREAST CANCER, 2024, 31 (01) : 53 - 62
  • [49] Overall survival (OS) and subsequent therapy patterns in Japanese patients with HR+/HER2-advanced breast cancer (ABC) treated with palbociclib (PAL) plus letrozole (LET) in first-line setting (1L)
    Takahashi, Masato
    Osako, Tomofumi
    Yasojima, Hiroyuki
    Inoue, Kenichi
    Kawashima, Masahiro
    Maeda, Hideki
    Ito, Mitsuya
    Sagara, Yasuaki
    Yonemori, Kan
    Hattori, Masaya
    Yamamoto, Naohito
    Tokunaga, Eriko
    Ohsumi, Shozo
    Yamamoto, Yutaka
    Ichikawa, Akemi
    Muramatsu, Yasuaki
    Masuda, Norikazu
    CANCER RESEARCH, 2024, 84 (09)
  • [50] Real-world effectiveness of palbociclib plus endocrine therapy in HR+/HER2-advanced breast cancer: final results from the POLARIS trial
    Tripathy, Debu
    Blum, Joanne L.
    Karuturi, Meghan S.
    Mccune, Steven
    Kurian, Sobha
    Moezi, Mehdi
    Anderson, Daniel
    Gauthier, Eric
    Zhang, Zhe
    Montelongo, Monica Z.
    Wang, Yao
    Rocque, Gabrielle B.
    ONCOLOGIST, 2024,
12345